Deep Dives, AI, Drug Development, Drug Discovery.
going to start by licensing compounds we find interesting,” he says, and “we are aiming to start our first AI-first phase drug within a year.” Other AI scale-ups have made similar promises. A pitch deck from 2017 describes BenevolentAI as having 24 “validated hypotheses in clinical and preclinical